Transfusion and Apheresis Science最新文献_第9页

INTRAOPERATIVE BLOOD RECOVERY FROM THE PATIENT BLOOD MANAGEMENT PERSPECTIVE: THE SERENISSIMA’ EXPERIENCE. 从患者血液管理的角度看术中血液恢复：小耳曼病的经验。

IF 1.2 4区医学

Transfusion and Apheresis Science Pub Date : 2026-02-01 Epub Date: 2026-01-30 DOI: 10.1016/j.transci.2025.104339

C. Rossi , F. Lazzari , D. Mangino , A. Marchesi , G. Gessoni , L. Altafini , M.A. Calò , G. Carretta

引用次数: 0

Safety and efficacy of G-CSF alone with pre-emptive plerixafor for autologous peripheral blood hematopoietic stem cell mobilization in newly diagnosed multiple myeloma G-CSF单独联合先发制人的普利沙用于新诊断的多发性骨髓瘤自体外周血造血干细胞动员的安全性和有效性。

IF 1.2 4区医学

Transfusion and Apheresis Science Pub Date : 2026-02-01 Epub Date: 2025-12-20 DOI: 10.1016/j.transci.2025.104304

Youssef Elemary , Waleed Sabry , Julie Stakiw , Mark Bosch , Hadi Goubran , James Sanayei , Shruthi Kodad , Rebecca MacKay , Jill Lacey , Sabuj Sarker , Mohamed Elemary

{"title":"Safety and efficacy of G-CSF alone with pre-emptive plerixafor for autologous peripheral blood hematopoietic stem cell mobilization in newly diagnosed multiple myeloma","authors":"Youssef Elemary , Waleed Sabry , Julie Stakiw , Mark Bosch , Hadi Goubran , James Sanayei , Shruthi Kodad , Rebecca MacKay , Jill Lacey , Sabuj Sarker , Mohamed Elemary","doi":"10.1016/j.transci.2025.104304","DOIUrl":"10.1016/j.transci.2025.104304","url":null,"abstract":"<div><h3>Background</h3><div>Mobilization failure remains a challenge in autologous stem cell transplantation for multiple myeloma (MM). Chemotherapy-based mobilization protocols, though effective, are associated with toxicity, hospitalization, and delay in transplant timing. We developed an algorithm-based protocol for peripheral blood stem cell (PBSC) mobilization using G-CSF alone, with pre-emptive Plerixafor based on peripheral blood CD34+ cell counts.</div></div><div><h3>Methods</h3><div>This retrospective study included MM patients who underwent stem cell collection between July 2013 and November 2023 at Saskatoon Cancer Centre. The mobilization protocol aimed to collect ≥ 4 × 10<sup>6</sup> CD34+ cells/kg, using daily CD34 count monitoring to determine the use of Plerixafor. Predefined thresholds guided the decision for Plerixafor administration and apheresis timing.</div></div><div><h3>Results</h3><div>Out of 176 patients (median age 61 years), 100 % achieved successful mobilization. Preemptive Plerixafor was required in 13.6 % of patients (n = 24), with 1–3 doses administered. The median number of apheresis days was 2 (range: 1–4). The median CD34 yield was 6.4 × 10<sup>6</sup> cells/kg. All patients received high-dose melphalan and underwent autologous transplant, with median neutrophil and platelet engraftment at 12 and 15 days, respectively. All patients were alive at day 100 post-transplant.</div></div><div><h3>Conclusion</h3><div>An algorithm-driven, G-CSF-only mobilization with pre-emptive Plerixafor use based on CD34 counts resulted in 100 % successful collections, early engraftment, minimal plerixafor use, and no mobilization failures. This approach avoids chemotherapy toxicity, optimizes Plerixafor use, and prevents transplant delays.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"65 1","pages":"Article 104304"},"PeriodicalIF":1.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145828560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Promoting technological advancement and innovation in transfusion medicine: Current approaches and future directions 促进输血医学的技术进步和创新：目前的方法和未来的方向。

IF 1.2 4区医学

Transfusion and Apheresis Science Pub Date : 2026-02-01 Epub Date: 2025-12-20 DOI: 10.1016/j.transci.2025.104298

Eric A. Gehrie, Garrett S. Booth, Burak Bahar

引用次数: 0

MOBILIZATION AND COLLECTION OF AUTOLOGOUS HSCS IN PATIENTS WITH MM IN DARATUMUMAB ERA. EXPERIENCE OF A SINGLE CENTER. 达拉单抗时代mm患者自体造血干细胞的动员和收集。单一中心的体验。

IF 1.2 4区医学

Transfusion and Apheresis Science Pub Date : 2026-02-01 Epub Date: 2026-01-30 DOI: 10.1016/j.transci.2025.104329

M. Giannoccaro , M. Colonna , C. Battista , C. Citarella , R. Frappampina , A. Tullo , R. Procacci , C. Lippolis , R. Galasso , A. Ostuni

引用次数: 0

THERAPY WITH ANTI-CD19 CAR-T CELLS IN AGGRESSIVE B-CELL LYMPHOMAS: SIE, SIDEM, GITMO RECOMMENDATIONS 抗cd19 car-t细胞治疗侵袭性b细胞淋巴瘤：sie， sidem， gitmo推荐

IF 1.2 4区医学

Transfusion and Apheresis Science Pub Date : 2026-02-01 Epub Date: 2026-01-30 DOI: 10.1016/j.transci.2025.104362

M. Montanari

引用次数: 0

THROMBOTIC MICROANGIOPATHY (TMA): THE POINT OF VIEW OF THE THERAPEUTIC APHERESIS (TA) SPECIALIST. 血栓性微血管病（tma）：治疗性采血（ta）专家的观点。

IF 1.2 4区医学

Transfusion and Apheresis Science Pub Date : 2026-02-01 Epub Date: 2026-01-30 DOI: 10.1016/j.transci.2025.104361

Marson P, Leahu A.I, Pavanello F, Tison T, Colpo A

引用次数: 0

Redistribution ratio in the clearance of environmental toxins by double filtration plasmapheresis 双重过滤血浆置换法清除环境毒素的再分配比

IF 1.2 4区医学

Transfusion and Apheresis Science Pub Date : 2026-02-01 Epub Date: 2026-01-02 DOI: 10.1016/j.transci.2026.104369

Yandy Marx Castillo-Aleman

{"title":"Redistribution ratio in the clearance of environmental toxins by double filtration plasmapheresis","authors":"Yandy Marx Castillo-Aleman","doi":"10.1016/j.transci.2026.104369","DOIUrl":"10.1016/j.transci.2026.104369","url":null,"abstract":"<div><div>While double filtration plasmapheresis (DFPP) has been used clinically for years, its role in environmental toxin removal remains underexplored. Even in other apheresis modalities used for poisoning and drug overdose, such as therapeutic plasma exchange and red blood cell exchange, few studies have examined the redistribution of such compounds from peripheral tissues back into plasma. In this context, we introduce the “<em>redistribution ratio</em>” (RR) as a novel metric to quantify this phenomenon. Calculated from circulating and collected pools before and after DFPP, RR offers insight into the post-procedural rebound of target analytes. High RR values suggest redistribution from extravascular compartments, commonly seen with lipophilic toxins or compounds that have a high volume of distribution and low plasma protein binding. In contrast, low or negative RR values may reflect limited redistribution due to intracellular sequestration, metabolic elimination, or irreversible tissue binding. To illustrate its clinical relevance, we present RR patterns from a cohort of patients with hyperlipoproteinemia(a) treated with DFPP, showing heterogeneous patterns across a range of environmental toxins. These findings support RR as a valuable complement to conventional pre- and post-procedure concentration metrics, with potential applications in refining DFPP timing and predicting rebound risk. RR may also serve as a surrogate marker for tissue toxin burden, although further validation is needed across broader toxin classes and apheresis platforms.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"65 1","pages":"Article 104369"},"PeriodicalIF":1.2,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145925069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CHARACTERIZATION OF AUTOLOGOUS PLATELET-RICH PLASMA (PRP) WITH CYCLIC VOLTAMMETRY (BIONOTE) 循环伏安法（bionote）测定自体富血小板血浆（prp）

IF 1.2 4区医学

Transfusion and Apheresis Science Pub Date : 2026-02-01 Epub Date: 2026-01-30 DOI: 10.1016/j.transci.2025.104337

P .Turchetti , C Gregorj , A. Zompanti , B Giannetti , A. Calaciura , G. Palazzo , C. Nobile , S. Grasso , M. Santonico , G. Pennazza , M. Vacca

引用次数: 0

VALIDATION OF A FLOW CYTOMETRY LABORATORY FOR CD34 CELLS COUNT 流式细胞术实验室cd34细胞计数的验证

IF 1.2 4区医学

Transfusion and Apheresis Science Pub Date : 2026-02-01 Epub Date: 2026-01-30 DOI: 10.1016/j.transci.2025.104344

Chiara Gregorj , Melania Di Cerbo , Anna Maria Morgia , Barbara Giannetti , Michele Prisciandaro , Daniela Fioravanti , Antonella Matteocci , Michele Vacca

引用次数: 0

Trends in cell collection and apheresis practices: Insights from a cross-sectional study on the use of Spectra Optia in collection and transplant centers 细胞收集和单采实践的趋势：来自收集和移植中心使用Spectra Optia的横断面研究的见解

IF 1.2 4区医学

Transfusion and Apheresis Science Pub Date : 2025-12-01 Epub Date: 2025-09-02 DOI: 10.1016/j.transci.2025.104251

Nabih Azar , Nelson J. Chao , Manuel Cliquennois , Maria Geske , Tomoko Henzan , Tamarah Kent , Pascale Poullin , Tsiporah B. Shore , Matthew Cawson , Hugo Fabre , Franziska Waltl

{"title":"Trends in cell collection and apheresis practices: Insights from a cross-sectional study on the use of Spectra Optia in collection and transplant centers","authors":"Nabih Azar , Nelson J. Chao , Manuel Cliquennois , Maria Geske , Tomoko Henzan , Tamarah Kent , Pascale Poullin , Tsiporah B. Shore , Matthew Cawson , Hugo Fabre , Franziska Waltl","doi":"10.1016/j.transci.2025.104251","DOIUrl":"10.1016/j.transci.2025.104251","url":null,"abstract":"<div><h3>Background</h3><div>This study, conducted among collection and transplant centers in France, Germany, Japan, the United Kingdom (UK), and the United States (USA), aimed to better understand current trends, challenges, and future directions in cell collection and apheresis practices, focusing on the Spectra Optia™ Apheresis System.</div></div><div><h3>Methods</h3><div>This cross-sectional study was conducted from July to November 2023 among facilities using the Spectra Optia™ Apheresis System, which could also be using other comparable cell collection technologies, with expertise in cell collection and therapeutics. Respondents completed an online questionnaire.</div></div><div><h3>Results</h3><div>Forty-four facilities (France: 9, Germany: 7, Japan: 7, UK: 6, USA: 15) consented to participate. Across participating centers, a marked trend towards autologous cell collections was evident in France (mean: 71 % of collections were for autologous purposes), Germany (74 %), UK (79 %), and USA (73 %). Among centers in Japan, a more balanced division between autologous (47 %) and allogeneic (53 %) collections was seen. Over half of all respondents indicated facing several key challenges, including issues related to supporting services, patients, logistics, purity, and technology. The respondents largely agreed that the cell therapy demand will increase over the next 3–5 years and estimated a growth of 10–200 %.</div></div><div><h3>Conclusions</h3><div>This study highlights the breadth of indications for which Spectra Optia is used, and the dynamic nature and growth prospects of the field. Innovation and standardization in apheresis technologies will be important to drive the potential of cell-based therapeutics.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 6","pages":"Article 104251"},"PeriodicalIF":1.2,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145020339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0